References
- Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J Clin 72, 7–33 (2022)
- Schouten, T. J. et al. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol 29, 5988–5999 (2022)
- Balaban, E. P., Mangu, P. B. & Yee, N. S. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 13, 265–269 (2016)
- Singh, R. R. & O’Reilly, E. M. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs vol. 80 647–669 Preprint at
https://doi.org/10.1007/s40265-020-01304-0 (2020) - Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M. & Becker, H. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers vol. 14 Preprint at
https://doi.org/10.3390/cancers14235926 (2022) - Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G. & Karamouzis, M. V. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World Journal of Gastrointestinal Oncology vol. 12 173–181 Preprint at
https://doi.org/10.4251/wjgo.v12.i2.173 (2020) - Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7–30 (2020)
- Von Hoff, D. D. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine 369, 1691–1703 (2013)
- Adamska, A. et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul 68, 77–87 (2018)
- Sinn, M. et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology 35, 3330–3337 (2017)
- Conroy, T. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine 379, 2395–2406 (2018)
- Ma, W. W. & Hidalgo, M. The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. Clinical Cancer Research 19, 5572–5579 (2013)
- Digiuseppe, J. A., Redston, M. S., Yeo, C. J., Kern, S. E. & Hruban, R. H. Communication P53-Independent Expression of the Cyclin-Dependent Kinase Inhibitor P21 in Pancreatic Carcinoma. American journal of Pathology vol. 147 (1995)
- Dardare, J., Witz, A., Merlin, J. L., Gilson, P. & Harlé, A. SMAD4 and the TGFB pathway in patients with pancreatic ductal adenocarcinoma. International Journal of Molecular Sciences vol. 21 Preprint at
https://doi.org/10.3390/ijms21103534 (2020) - Bartsch, D. K. et al. CDKN2A Germline Mutations in Familial Pancreatic Cancer. (2002) doi:10.1097/01.SLA0000036393.89509.4E
- Lomberk, G. et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun 9, (2018)
- Hayashi, A., Hong, J. & Iacobuzio-Donahue, C. A. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 18, 469–481 (2021)
- Montalto, F. I. & De Amicis, F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells vol. 9 Preprint at
https://doi.org/10.3390/cells9122648 (2020) - Goodwin, C. M. et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res 83, 141–157 (2023)
- Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. & Büch, T. cancers Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel) 13, 634 (2021)
- Licht, J. D. & Bennett, R. L. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics vol. 13 Preprint at
https://doi.org/10.1186/s13148-021-01100-x (2021) - Knoche, S. M. et al. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLoS One 17, (2022)
- Simões-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Molecular Neurodegeneration vol. 8 Preprint at
https://doi.org/10.1186/1750-1326-8-7 (2013) - van Kampen, J. G. M. et al. Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40, 656–664 (2014)
- Goto, K. et al. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep 6, 38407 (2016)
- Sun, T. et al. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer 10, 5638–5645 (2019)
- Ritter, C. et al. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Sci Rep 6, 21678 (2016)
- Ugurel, S. et al. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Cancer Immunology, Immunotherapy 68, 983–990 (2019)
- Mustafa, A.-H. M. & Krämer, O. H. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev 75, 35 (2023)
- Ashry, R. et al. NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor. Cancers (Basel) 15, (2023)
- Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development. Cell 99, 247–257 (1999)
- Scourzic, L., Mouly, E. & Bernard, O. A. TET proteins and the control of cytosine demethylation in cancer. Genome Med 7, (2015)
- Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415–428 (2002)
- Jeziorska, D. M. et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. Proc Natl Acad Sci U S A 114, E7526–E7535 (2017)
- Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001)
- Herman, J. G. & Baylin, S. B. Gene Silencing in Cancer in Association with Promoter Hypermethylation. New England Journal of Medicine 349, 2042–2054 (2003)
- Zhu, J. et al. Integrating genome and methylome data to identify candidate DNA methylation biomarkers for pancreatic cancer risk. Cancer Epidemiology Biomarkers and Prevention 30, 2079–2087 (2021)
- Ozturk, H. et al. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Dev Cell 57, 1331–1346.e9 (2022)
- Sato, N., Matsubayashi, H., Abe, T., Fukushima, N. & Goggins, M. Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling. Clinical Cancer Research 11, 4681–4688 (2005)
- Eyres, M. et al. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Gastroenterology 161, 653–668.e16 (2021)
- Xiao, Q. et al. Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation. Cancer Res 76, 5395–5404 (2016)
- Zhang, M. et al. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduct Target Ther 6, (2021)
- Tang, R.-Z. et al. DNA methyltransferase 1 and Krüppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis. J Mol Cell Cardiol 128, 11–24 (2019)
- Mees, S. T. et al. EP300—A miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 126, 114–124 (2010)
- Cai, M. H. et al. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine. Sci Rep 8, (2018)
- Klieser, E. et al. Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World J Gastrointest Oncol 7, 473–483 (2015)
- Brand, M. et al. Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions. ACS Chem Biol 10, 22–39 (2015)
- Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and Cancer: Going beyond transcriptional regulation. Molecular Cancer vol. 17 Preprint at
https://doi.org/10.1186/s12943-018-0915-9 (2018) - Shi, J. & Vakoc, C. R. The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. Molecular Cell vol. 54 728–736 Preprint at
https://doi.org/10.1016/j.molcel.2014.05.016 (2014) - Greer, E. L. & Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nature Reviews Genetics vol. 13 343–357 Preprint at
https://doi.org/10.1038/nrg3173 (2012) - Chen, Y. et al. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduction and Targeted Therapy vol. 5 Preprint at
https://doi.org/10.1038/s41392-020-00252-1 (2020) - Benitz, S. et al. Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis. Gut 68, 2007 (2019)
- Andricovich, J. et al. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 33, 512–526.e8 (2018)
- Rao, R. A. et al. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep 5, (2015)
- Ougolkov, A. V., Bilim, V. N. & Billadeau, D. D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clinical Cancer Research 14, 6790–6796 (2008)
- Toll, A. D. et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 41, 1205–1209 (2010)
- Han, T. et al. EZH2 Promotes Cell Migration and Invasion but Not Alters Cell Proliferation by Suppressing E-Cadherin, Partly through Association with MALAT-1 in Pancreatic Cancer. Oncotarget vol. 7
www.impactjournals.com/oncotarget/ - Aghdassi, A. et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61, 439 (2012)
- Song, Y., Washington, M. K. & Crawford, H. C. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70, 2115–2125 (2010)
- Roe, J. S. et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170, 875–888.e20 (2017)
- Hessmann, E., Johnsen, S. A., Siveke, J. T. & Ellenrieder, V. Epigenetic treatment of pancreatic cancer: Is there a therapeutic perspective on the horizon? Gut 66, 168–179 (2017)
- Roca, M. S. et al. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Journal of Experimental and Clinical Cancer Research 41, (2022)
- Romeo, M. A. et al. Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1. Discover Oncology 14, (2023)
- Qu, L. et al. The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunology, Immunotherapy 71, 2313–2323 (2022)
- Xiong, W., Gao, Y., Wei, W. & Zhang, J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 7, 837–846 (2021)
- Zeng, Y. et al. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene 41, 3859–3875 (2022)
- Kuo, T. L., Cheng, K. H., Chen, L. T. & Hung, W. C. ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance. iScience 26, (2023)
- Russell, M. A. et al. HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet β-Cells From Donors With Type 1 Diabetes. Diabetes 68, 988–1001 (2019)
- Sixto-López, Y. et al. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. Sci Rep 10, (2020)
- Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132, 10842–10846 (2010)
- Kong, Y. et al. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther 10, 1591–1599 (2011)
- Estiu, G. et al. On the inhibition of histone deacetylase 8. Bioorg Med Chem 18, 4103–4110 (2010)
- Charrier, C. et al. Synthesis and Modeling of New Benzofuranone Histone Deacetylase Inhibitors that Stimulate Tumor Suppressor Gene Expression. J Med Chem 52, 3112–3115 (2009)
- Khochbin, S., Verdel, A., Lemercier, C. & Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11, 162–166 (2001)
- Wang, D.-F., Helquist, P., Wiech, N. L. & Wiest, O. Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases. J Med Chem 48, 6936–6947 (2005)
- Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21, 1163–1171 (2015)
- Maietta, I. et al. Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells. Pharmaceuticals 15, (2022)
- Bai, J., Demirjian, A., Sui, J., Marasco, W. & Callery, M. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348, 1245–1253 (2006)
- Christmas, B. J. et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res 6, 1561–1577 (2018)
- Poklepovic, A. S. et al. A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer. Journal of Clinical Oncology 39, e16268–e16268 (2021)
- Streubel, G. et al. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep 11, (2021)
- Wang, Z. et al. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell 37, 834–849.e13 (2020)
- Chan, E. et al. Phase i trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology 119, 312–318 (2016)
- Ubbert, M. L. ¨ et al. MD 12,13 ; Hans-Walter Lindemann, MD 14 ; Carsten Müller-Tidow, MD 5,15,16 ; Gerhard Heil. J Clin Oncol 17, 257–270
- Meier, R. et al. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation. Blood Cancer J 12, (2022)
- Li, Y. et al. Alterations of specific chromatin conformation affect ATRA-induced leukemia cell differentiation. Cell Death Dis 9, (2018)
- Trus, M. R. et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 19, 1161–1168 (2005)
- Luu, T. et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol 84, 1201–1208 (2019)
- Neureiter, D. et al. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42, 103–116 (2007)
- Guo, Z. et al. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors. J Med Chem 65, 6573–6592 (2022)
- He, S. et al. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angewandte Chemie International Edition 59, 3028–3032 (2020)
- Lassen, U. et al. A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103, 12–17 (2010)
- Ikeda, M. et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Invest New Drugs 37, 109–117 (2019)